Text Size: a  |   a 

MMJ Files Patent on Part-Cannabinoid and Part-Non-Cannabinoid Treatment for MS

January 9, 2018

MMJ International Holdings is seeking a patent for a part-cannabinoid and part-non-cannabinoid treatment to be used for multiple sclerosis and other diseases.  In a news release the company said they filed a patent request ahead of the Phase 2 trials of the formulation. MMJ Bioscience, an affiliate of MMJ International Holdings, developed the therapy.

Neurology professor at the New York State MS Consortium, Dr. Bianca Weinstock-Guttman, is to oversee the study of the therapy’s potential ability to help those with progressive MS.

“Entering Phase 2 trials is a highly significant point in the development of our cannabis-based medicines,” announced MMJ spokesman Michael Sharpe. “These trials will allow us to demonstrate efficacy in a limited number of subjects and to establish the necessary dosage regimen and delivery mechanisms to provide the most effective relief to sufferers from the acute pain and spasticity associated with MS.”

MMJ Bioscience submitted an application in November 2017 for a patent covering the delivery of a formulation that would be tested in a Phase 2 trial for MS. This trial will be MMJ’s first study of a cannabis-based treatment made for the painful and spastic symptoms associated with MS. The trial is expected to behind in early 2018 in New York. 
The company aims to bring cannabis-based medicines to market by 2020. The products have been designed to provide patients with the medical advantages of cannabis without the psychoactive side effects or health risks associated with smoking.

If approved by the U.S. Food and Drug Administration approves a cannabis-based medicine, patients in states where cannabis products have yet to become legal would have access to them, as they would be sold in pharmacies like other pharmaceuticals.

The company stated, “MMJ BioScience’s discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.”